Nt2 , - I will agree with you except that our comb
Post# of 145351
![](/assets/46931549/no_avatar_available_thumb.jpg)
To be in mono patient must have VL < 50 copies /ml.
as our combo is for MDR 2 and 3 patients ,
and the only competition with efficacy of 45% and severe side effects is Maraviroc for MDR 2 and 3,
and for MDR 3 IV Ibalizumab with 43% efficacy and some side effects.
Our combo is an emergency , and it is not treated like that by FDA.!!!!!!
and IMO this is a big problem .....
I am curious what will happen with BTD.
IMO as always.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)